Literature DB >> 14668549

The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin.

Jeffrey D Seidman1, Iren Horkayne-Szakaly, Moutaz Haiba, Charles R Boice, Robert J Kurman, Brigitte M Ronnett.   

Abstract

Advances over the past decade suggest a need to reassess the distribution of ovarian surface epithelial tumors. A series of 220 consecutive invasive ovarian carcinomas, including carcinosarcomas and peritoneal carcinomas, was reviewed. Notable findings include: 7% of tumors were carcinosarcomas; 22% of cases of peritoneal serous carcinomatosis were of peritoneal origin; <3% of cases were mucinous carcinomas; and only one malignant Brenner tumor (0.5%) and no pure transitional cell carcinomas were identified. If peritoneal carcinomas, carcinosarcomas, and mixed carcinomas with a serous component are combined with serous carcinomas, this group accounts for 78% of all cases and 87% of advanced stage cases, suggesting a greater uniformity to epithelial ovarian cancer than previously appreciated.

Entities:  

Mesh:

Year:  2004        PMID: 14668549     DOI: 10.1097/01.pgp.0000101080.35393.16

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  154 in total

1.  Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman
Journal:  Cancer       Date:  2010-09-22       Impact factor: 6.860

2.  Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.

Authors:  Katherine C Kurnit; Abdulrahman K Sinno; Bryan M Fellman; Aaron Varghese; Rebecca Stone; Anil K Sood; David M Gershenson; Kathleen M Schmeler; Anais Malpica; Amanda N Fader; Michael Frumovitz
Journal:  Obstet Gynecol       Date:  2019-12       Impact factor: 7.661

3.  Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.

Authors:  Yali Zhai; Rork Kuick; Courtney Tipton; Rong Wu; Michael Sessine; Zhong Wang; Suzanne J Baker; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2015-09-15       Impact factor: 7.996

4.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Authors:  Weiwei Shan; Imelda Mercado-Uribe; Jing Zhang; Daniel Rosen; Shiwu Zhang; Jianjun Wei; Jinsong Liu
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

5.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 6.  Unmasking the complexities of mucinous ovarian carcinoma.

Authors:  Michael Frumovitz; Kathleen M Schmeler; Anais Malpica; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2010-03-23       Impact factor: 5.482

Review 7.  Mucinous tumors of the ovary: current thoughts on diagnosis and management.

Authors:  Jubilee Brown; Michael Frumovitz
Journal:  Curr Oncol Rep       Date:  2014-06       Impact factor: 5.075

8.  Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma.

Authors:  Hanxiao Wang; Stefanie Galbán; Rong Wu; Brittany M Bowman; Amanda Witte; Katrin Vetter; Craig J Galbán; Brian D Ross; Kathleen R Cho; Alnawaz Rehemtulla
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

9.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

Review 10.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.